menu
    • menu
    [{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RVAC Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RVAC Medicines \/ Undisclosed"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RVAC Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RVAC Medicines \/ Undisclosed"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"RVM-V001","moa":"SARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RVAC Medicines \/ RVAC Medicines","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ RVAC Medicines"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RVAC Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Undisclosed"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RVAC Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Undisclosed"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Pavilion Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series B Financing","leadProduct":"mRNA COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RVAC Medicines","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"RVAC Medicines \/ Pavilion Capital","highestDevelopmentStatusID":"4","companyTruncated":"RVAC Medicines \/ Pavilion Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by RVAC Medicines

    Menu

    RVAC Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in He...

                            Details : RVM-V001 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Communicable Diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 28, 2023

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : GenScript ProBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA ...

                            Details : Under the agreement, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. The partnership will accelerate its clinical manufacturing of future mRNA-based vaccines targeting infectious diseases such as RSV...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : GenScript ProBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore

                            Details : RVM-V001 is a mRNA-based COVID-19 vaccine candidate for which the company has secured approval from the HSA to initiate Phase 1B clinical trial in Singapore to evaluate product's safety and immunogenicity.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 20, 2023

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates

                            Details : Phase 1 study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single IM injection in healthy adults. Three dose levels will be evaluated, with progression from low- to high-dose level based on the assessment of safe...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 21, 2022

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

                            Details : RVM-V001 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Communicable Diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            RVAC Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA COVID Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Pavilion Capital

                            Deal Size : $140.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing C...

                            Details : Proceeds from this will be used for preclinical and clinical development of the mRNA vaccine and therapeutics programs and building world class R&D centers and manufacturing capabilities, including R&D center in Singapore and manufacturing facilities in ...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : mRNA COVID Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Pavilion Capital

                            Deal Size : $140.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth